Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2009

Commission File Number: 001-31368

 

 

SANOFI-AVENTIS

(Translation of registrant’s name into English)

 

 

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  x        Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):             

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨        No  x

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-            

 

 

 

In September 2009, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.

Exhibit List

 

Exhibit No.

   

Description

Exhibit 99.1    Press release dated September 28, 2009: Sanofi-aventis announces dismissal of U.S. Securities law suit regarding Zimulti® (rimonabant)
Exhibit 99.2    Press release dated September 29, 2009: Sanofi-aventis launches major insulin research program in partnership with the international scientific community.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: September 30, 2009   SANOFI-AVENTIS
  By  

/s/    John Felitti

  Name:   John Felitti
  Title:   Director, U.S. & International Securities Law

 

3

Exhibit Index

 

Exhibit No.

   

Description

Exhibit 99.1

    Press release dated September 30, 2009: Sanofi-aventis announces dismissal of U.S. Securities law suit regarding Zimulti® (rimonabant)

Exhibit 99.2

    Press release dated September 29, 2009: Sanofi-aventis launches major insulin research program in partnership with the international scientific community.

 

4